Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R. Harbeck N, et al. Among authors: lesche r. J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18. J Clin Oncol. 2008. PMID: 18711169
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Maier S, et al. Among authors: lesche r. Eur J Cancer. 2007 Jul;43(11):1679-86. doi: 10.1016/j.ejca.2007.04.025. Epub 2007 Jun 29. Eur J Cancer. 2007. PMID: 17601725
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW. Nimmrich I, et al. Among authors: lesche r. Breast Cancer Res Treat. 2008 Oct;111(3):429-37. doi: 10.1007/s10549-007-9800-8. Epub 2007 Oct 28. Breast Cancer Res Treat. 2008. PMID: 17965955
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW. Hartmann O, et al. Among authors: lesche r. Clin Cancer Res. 2009 Jan 1;15(1):315-23. doi: 10.1158/1078-0432.CCR-08-0166. Clin Cancer Res. 2009. PMID: 19118060 Clinical Trial.
DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J, Wheeler T. Weiss G, et al. Among authors: lesche r. J Urol. 2009 Apr;181(4):1678-85. doi: 10.1016/j.juro.2008.11.120. Epub 2009 Feb 23. J Urol. 2009. PMID: 19233404
CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW. Dietrich D, et al. Among authors: lesche r. BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247. BMC Cancer. 2010. PMID: 20515469 Free PMC article.
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study.
Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, Schmitt M, Lesche R, Maier S, Timmermans M, Foekens JA, Martens JW. Golouh R, et al. Among authors: lesche r. Breast Cancer Res Treat. 2008 Jul;110(2):317-26. doi: 10.1007/s10549-007-9724-3. Epub 2007 Sep 13. Breast Cancer Res Treat. 2008. PMID: 17874182
72 results